Correction for Ebrahem et al., Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration

MEDICAL SCIENCES. For the article “Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration,” by Quteba Ebrahem, Kutralanathan Renganathan, Jonathan Sears, Amit Vasanji, Xiaorong Gu, Liang Lu, Robert G. Salomon, John W. Crabb, and Bela Anand-Apte, which appeared in issue 36, September 5, 2006, of Proc Natl Acad Sci USA (103:13480–13484; first published August 25, 2006; 10.1073/pnas.0601552103), the authors note that the conflict of interest statement, “J.W.C. is a consultant for Alcon Research Ltd. and obtains research funding from Merck & Co. and Johnson & Johnson. J.W.C. and R.G.S. each have a license for CEP as an inventor from Franz Biomarkers LLC,” should read: “J.W.C. is a consultant for Alcon Research Ltd. and obtains research funding from Merck & Co. and Johnson & Johnson. J.W.C. and R.G.S. each have licensed to Frantz Biomarkers, LLC, the development of CEP as a risk marker for AMD.”